Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine

Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine

Background: Azacitidine (AZA) is the standard treatment for patients with high-risk myelodysplastic syndromes (MDS). The impact of skeletal muscle depletion (SMD), which is associated with outcomes of hematological malignancies, on the clinical course of MDS patients treated with AZA was investigate...

Full description

Bibliographic Details
Main Authors: Eri Takada, Nobuhiko Nakamura, Yuto Kaneda, Kenji Fukuno, Shin Lee, Kei Fujita, Tetsuji Morishita, Yoshikazu Ikoma, Takuro Matsumoto, Hiroshi Nakamura, Junichi Kitagawa, Nobuhiro Kanemura, Senji Kasahara, Takeshi Hara, Hisashi Tsurumi, Masahito Shimizu
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Hematology Reports
Subjects:
myelodysplastic syndrome
azacitidine
skeletal muscle depletion
hematological toxicity
Online Access:https://www.mdpi.com/2038-8330/16/1/12

Similar Items

Similar Items